A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection.
One of the most common life-threatening infections in immunosuppressive patients, like AIDs patients, is cryptococcal meningitis or meningoencephalitis. Current therapeutic options are mostly ineffective and mortality rates remain high. Hydrophobic antifungal drug Amphotericin B (AmB), has become a golden standard in severe systemic fungal infection therapy. However, most AmB commercial formulations, including deoxycholate AmB and lipid formulations of AmB, show poor penetration into the CNS and difficulty to reach the therapeutic levels. To improve the CNS permeability of AmB, we have successfully developed an effective brain-targeting polymeric micellar system with angiopep-2 modified, named Angiopep-PEG-PE/AmB polymeric micelles. An immunosuppressive murine model with Cryptococcus neoformans meningoencephalitis (CNME) was established to evaluate the CNS penetration efficiency and antifungal treatment efficacy of the AmB-incorporated brain-vectored polymeric micellar formulation, compared with the AmB commercial formulations. After three consecutive days of i.v. administration, the results showed that the group treated with Angiopep-PEG-PE/AmB achieved the greatest treatment efficacy, which reached the highest AmB level in brain, reduced the brain fungal burden significantly, decreased histopathological severity and prolonged the median survival time. The increased treatment efficacy could be attributed to the brain-targeting delivery system promoted AmB crossing the BBB and penetrating into the brain to reach the therapeutic concentration. The underlying mechanism was also explored in this work. Therefore, the brain-targeting delivery system could have potential and promising implications for treatment of intracerebral fungal infection.
Key Laboratory of Smart Drug Delivery, Ministry of Education & PLA, Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
Kun
K
Shao
Jiqin
J
Wu
Zhongqing
Z
Chen
Shixian
S
Huang
Jianfeng
J
Li
Liya
L
Ye
Jinning
J
Lou
Liping
L
Zhu
Chen
C
Jiang
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors; D000666:Amphotericin B / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry; D001812:Blood-Brain Barrier / Q000378:metabolism; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000302:isolation & purification; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy*; D008590:Meningoencephalitis / Q000188:drug therapy; D051379:Mice; D008823:Micelles; D018613:Microscopy, Confocal; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry; D013050:Spectrometry, Fluorescence; D014700:Verapamil / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; C531860:Angiopep-2; D000935:Antifungal Agents; D004337:Drug Carriers; D008823:Micelles; D010455:Peptides; D011092:Polyethylene Glycols; D000666:Amphotericin B; D014700:Verapamil